Login to Your Account

Oxford BioTherapeutics, GSK in $370M Cancer Drug Deal

By Donna Young

Tuesday, May 19, 2009
Smallish UK biotech Oxford BioTherapeutics Ltd. stands to gain $370 million under a new partnership with drug giant GlaxoSmithKline plc to discover, develop and commercialize therapeutic antibodies aimed at treating primary, metastatic and recurring forms of cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription